MedTrace Logo

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

NCT01155817 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-04-15

No results posted yet for this study

Summary

PRIMARY OBJECTIVES:

Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD.

SECONDARY OBJECTIVES:

Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.

Conditions

  • Bone Marrow Transplant Failure
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell, Peripheral

Interventions

DRUG

Nilotinib

200, 400, 800, oral

Sponsors & Collaborators

Principal Investigators

  • David Miklos · Stanford University

  • George Chen · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-12-31
Completion
2013-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01155817 on ClinicalTrials.gov